

## अनुबंध | Contract



अनुबंध क्रमांक | Contract No: GEMC-511687724592062

अनुबंध तिथि | Generated Date : 10-May-2024

## संगठन विवरण | Organisation Details

प्ररूप | Type : State Government  
मंत्रालय | Ministry : -  
विभाग | Department : Labour and Employment Department Goa  
संगठन का नाम | Organisation Name : N/A  
कार्यालय क्षेत्र | Office Zone: Panchdeep bhawan Patti panjim Goa

## खरीदार विवरण | Buyer Details

पद | Designation : Pharmacist  
संपर्क नंबर | Contact No. : -  
ईमेल आईडी | Email ID : buyer4.ledg.ga@gembuyer.in  
जीएसटीआईएन | GSTIN : -  
पता | Address : O/O Administrative Medical Officer ,Employees State Insurance Corporation, Panchdeep Bhawan , Patto, Panaji, , NORTH GOA, GOA-403001, India

## वित्तीय स्वीकृति विवरण | Financial Approval Detail

आईएफडी सहमति | IFD Concurrence : No  
प्रशासनिक अनुमोदन का पदनाम | Designation of Administrative Approval: DDO  
वित्तीय अनुमोदन का पदनाम | Designation of Financial Approval : DDA

## भुगतान प्राधिकरण विवरण | Paying Authority Details

Role: PAO  
भुगतान का तरीका | Payment Mode: Internet Banking  
पद | Designation : Deputy Director Accounts  
ईमेल आईडी | Email ID : pao3.ledg.ga@gembuyer.in  
जीएसटीआईएन | GSTIN : -  
पता | Address : O/O Administrative Medical Officer,, PANCHDEEP BHAWAN, PATTO, PANAJI, GOA, North Goa, GOA-403001, India

## विक्रेता विवरण | Seller Details

जेम विक्रेता आईडी | GeM Seller ID : CC28180000120672  
कंपनी का नाम | Company Name : KARNATAKA ANTIBIOTICS AND PHARMACEUTICALS LIMITED  
संपर्क नंबर | Contact No. : 08023571590  
ईमेल आईडी | Email ID : instmkt@kaplindia.com  
पता | Address : KAPL HOUSE, ARKA THE BUSINESS CENTRE, PLOT NO. 37, SITE NO. 34/4,,NTTF MAIN ROAD, 2ND PHASE, PEENYA INDUSTRIAL AREA, BANGALORE, Bangalore, KARNATAKA-560058, -  
एमएसएमई पंजीकरण संख्या | MSME Registration number : -  
जीएसटीआईएन | GSTIN: 32AAACK5675N1Z7 (B) , 20AAACK5675N1ZC (B) , 21AAACK5675N1ZA (B) , 22AAACK5675N1Z8 (B) , 05AVPPS5216G1ZD (B) , 19AAACK5675N1ZV (B) , 09AAACK5675N1ZW (B) , 27AAACK5675N1ZY (B) , 29AAACK5675N1ZU (B) , 33AAACK5675N2Z4 (B) , 08AAACK5675N1ZY (B) , 32AAACK5675N1Z7 (B) , 29AAACK5675N1ZU (B) , (R) , 04AAACK5675N1Z6 (B) , 32AAACK5675N1Z7 (B) , 24AAACK5675N1Z4 (B) , (B) , 23AAACK5675N1Z6 (B) , 03AAACK5675N1Z8 (B) , 10AAACK5675N1ZD (B) , 18AAACK5675N1ZX (B) , 07AAACK5675N1Z0 (B) , 36AAACK5675N1ZZ (B)

\*जिसके नाम के पक्ष में GST/TAX इनवॉइस पेश किया जाएगा | GST / Tax invoice to be raised in the name of - Consignee

वितरण निर्देश | Delivery Instructions : NA

## उत्पाद विवरण | Product Details

| #                                            | आइटम विवरण   Item Description                                                                                                                                                                                                                                                                                                                                                                                                                                          | आइटम विवरण   Ordered Quantity | इकाई   Unit | इकाई मूल्य (INR)   Unit Price (INR) | कर विभाजन (INR)   Tax Bifurcation (INR) | मूल्य (INR में सभी शुल्क और कर सहित)   Price (Inclusive of all Duties and Taxes in INR) |
|----------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|-------------|-------------------------------------|-----------------------------------------|-----------------------------------------------------------------------------------------|
| 1                                            | उत्पाद का नाम   Product Name : Unbranded OFLOXACIN IP 200 MG + ORNIDAZOLE 500 MG Tablet<br>ब्रांड   Brand : NA<br>ब्रांड प्रकार   Brand Type : Unbranded<br>कैटलॉग की स्थिति   Catalogue Status: Catalogue not verified by OEM<br>कैसे बेचा जा रहा है   Selling As : Reseller not verified by OEM<br>श्रेणी का नाम और चतुर्थांश   Category Name & Quadrant : OFLOXACIN + ORNIDAZOLE (Q3)<br>मॉडल   Model: Tablet<br>एचएसएन कोड   HSN Code: HSN not specified by seller | 40                            | box         | 253.59                              | NA                                      | 10,143.6                                                                                |
| कुल ऑर्डर मूल्य   Total Order Value (in INR) |                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                               |             |                                     |                                         | 10,143.6                                                                                |

## परेषिती विवरण | Consignee Detail

| क्र.सं.   S.No | परेषिती   Consignee | वस्तु   Item | लॉट नंबर   Lot No. | मात्रा   Quantity | दिनांक के बाद डिलीवरी शुरू करना है   Delivery Start | वितरण पूरा कब तक करना है   Delivery To Be |
|----------------|---------------------|--------------|--------------------|-------------------|-----------------------------------------------------|-------------------------------------------|
|----------------|---------------------|--------------|--------------------|-------------------|-----------------------------------------------------|-------------------------------------------|

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                         |                                                                   |                                                      |               |             |              |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|------------------------------------------------------|---------------|-------------|--------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                         |                                                                   |                                                      |               | After       | Completed By |
| 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | पद   Designation : Pharmacist<br>ईमेल आईडी   Email ID : con3.ledg.ga@gembuyer.in<br>संपर्क   Contact : -<br>जीएसटीआईएन   GSTIN : -<br>पता   Address : ESI Dispensary, Corlim, Plot No. 1, Corlim Industrial Estate, Corlim, Ilhas, Goa,<br>NORTH GOA, GOA-403110, India | Unbranded OFLOXACIN<br>IP 200 MG +<br>ORNIDAZOLE 500 MG<br>Tablet | -                                                    | 40            | 10-May-2024 | 09-Jul-2024  |
| Product Specification for Unbranded OFLOXACIN IP 200 MG + ORNIDAZOLE 500 MG Tablet                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                         |                                                                   |                                                      |               |             |              |
| विनिर्देश   Specification                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                         | उप-विनिर्देश   Sub-Spec                                           |                                                      | मूल्य   Value |             |              |
| GENERAL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Product description                                                                                                                                                                                                                                                     |                                                                   | OFLOXACIN IP 200 MG + ORNIDAZOLE 500 MG              |               |             |              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Conformity to standard                                                                                                                                                                                                                                                  |                                                                   | IP                                                   |               |             |              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Strength                                                                                                                                                                                                                                                                |                                                                   | 200 mg + 500 mg                                      |               |             |              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Dosage form                                                                                                                                                                                                                                                             |                                                                   | Tablet                                               |               |             |              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Route of Administration                                                                                                                                                                                                                                                 |                                                                   | ORAL                                                 |               |             |              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Shelf life (in months)                                                                                                                                                                                                                                                  |                                                                   | 24                                                   |               |             |              |
| CERTIFICATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Drug Manufacturing License No                                                                                                                                                                                                                                           |                                                                   | NB-152/84 DT.14.05.1984                              |               |             |              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Drug Manufacturing License Date                                                                                                                                                                                                                                         |                                                                   | 07/07/2014                                           |               |             |              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | GMP Certification No                                                                                                                                                                                                                                                    |                                                                   | GMP-DCD/CR-114/SPL.CL/2017.18                        |               |             |              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | GMP Certification Date                                                                                                                                                                                                                                                  |                                                                   | 17/05/2017                                           |               |             |              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | WHO GMP Certification No                                                                                                                                                                                                                                                |                                                                   | DCD/SPL.CL-1/CR/2017-2018                            |               |             |              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | WHO GMP Certification Date                                                                                                                                                                                                                                              |                                                                   | 23/10/2017                                           |               |             |              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Non-conviction Certificate No                                                                                                                                                                                                                                           |                                                                   | DCD/Spl.CI-I/CR-1462/17-                             |               |             |              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Non-conviction Certificate Date                                                                                                                                                                                                                                         |                                                                   | 09/01/2018                                           |               |             |              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Certification for manufacturing premises                                                                                                                                                                                                                                |                                                                   | NA                                                   |               |             |              |
| PACKING                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Other statutory markings on the packing of the drug                                                                                                                                                                                                                     |                                                                   | Keep in a cool dry place. Store protected from light |               |             |              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Primary packing                                                                                                                                                                                                                                                         |                                                                   | 10                                                   |               |             |              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Secondary Packing                                                                                                                                                                                                                                                       |                                                                   | 10X10                                                |               |             |              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Final Packing                                                                                                                                                                                                                                                           |                                                                   | 80X10X10                                             |               |             |              |
| टिप्पणी   Note:: Seller has given an undertaking that it has made arrangements for getting the stores from an authorized distributor / dealer / channel partner of the OEM of the offered product. At the time of delivery of goods, Seller will provide necessary chain documents (in the form of GST Invoice) to prove that the supplied goods are genuine and are being sourced from an authorized distributor / dealer / channel partner of the OEM. In case of any complaint about genuineness of the supplied products, Seller shall be responsible for providing genuine replacement supplies. |                                                                                                                                                                                                                                                                         |                                                                   |                                                      |               |             |              |
| ईपीबीजी विवरण   ePBG Detail                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                         |                                                                   |                                                      |               |             |              |
| NA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                         |                                                                   |                                                      |               |             |              |
| नियम और शर्तें   Terms and Conditions                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                         |                                                                   |                                                      |               |             |              |
| 1. Special terms and conditions- Version:2 effective from 28-07-2021                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                                         |                                                                   |                                                      |               |             |              |
| 1.1 Special Terms and Conditions for 103 Drugs reserved for Central Public Sector Enterprises (CPSEs)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                         |                                                                   |                                                      |               |             |              |
| 1. Pharmaceuticals Purchase Policy by Department of Pharmaceuticals, Ministry of Chemical and Fertilizers, GOI in respect of 103 (one hundred and three) medicines would be valid till the final closure/strategic disinvestment of the pharma PSUs as per OM No. F.No.50017/01/2018-PSU dated 04 <sup>th</sup> December, 2019                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                         |                                                                   |                                                      |               |             |              |
| 2. Pharmaceuticals Purchase Policy will extend only to Central Public Sector Enterprises (CPSEs) under the administrative control of Department of Pharmaceuticals and their subsidiaries where Government of India owns 51%(fifty one percent) or above shares.                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                         |                                                                   |                                                      |               |             |              |
| 3. The pricing of these drugs would be done by National Pharmaceutical Pricing Authority (NPPA) using the cost based formula as mentioned in the Drugs Price Control Order, 1995 as per the latest amendments.In case the prices are revised by the NPPA, prices will be changed accordingly, and revised rate shall be applicable for all supplies made on or after the date of revision.                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                         |                                                                   |                                                      |               |             |              |

4. All Provision of Drug & Cosmetic act 1940 as amended till date and rules made there under will always be applicable.
5. CPSEs should hold valid drug license/import License, valid GMP/WHO GMP, valid Non conviction certificates from the concerned drug controller for the manufacturer/import of the medicine/drug. If revalidation of drug license has been applied for, the buyer should be informed accordingly and the copy of application to State Drug/Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date.
6. Loan license arrangement shall not be allowed under any circumstances.
7. Each batch of the drugs shall be dispatched under self-certification scheme duly supported by their own test reports. The consignees shall be at liberty to draw control samples and send it to laboratories approved by the State Drug Controllers / run by State Government/NABL approved laboratories without any intimation to the supplier. If this new test report is contradictory with the test report submitted by CPSE, the cost incurred on the whole process of testing shall be borne by the seller and the whole failed batch will be replaced by the CPSE. Also, if at any stage of use the supplies are found substandard, the whole failed batch will be replaced by the CPSE, even if the supplies have been consumed in good faith and the facts will be notified to the Drug Controller if India / State Drug Controller for taking necessary action.
8. The classification of defects into different categories will as per guidelines issued by the Drug Controller of India and action will be taken accordingly.
9. The supplies should not have passed more than 1/6th of the total shelf life of the product at the time of receipt of the store.
10. It is the responsibility of the seller to intimate Government e-Marketplace (GEM) about any quality complaints of the drugs/medicines reported by any buyer/consignee.
11. Order should be placed for the quantities in multiples of the primary packing.
12. Minimum lead time for delivery will be 45 days.
13. Bar coding - The buyer can opt for bar coding only if the order placed on any CPSE is for minimum quantity of tablet/capsule- 5.0 lakhs numbers or injection- 1.0 lakh number or ointment- 25000 numbers or syrup- 5000 numbers. The bar coding will be GSI complied.
14. Labels of all containers, cartons, vials, strips etc. should invariably be marked in block letters "Government supply not for sale" with the indelible ink for supplies made to the Government.
15. PACKING & MARKING: Packing and Marking will be as per provisions of applicable Pharmacopeia and as specified under Drugs and Cosmetics Act. 1940 as amended to date. In addition-
  1. Primary and Secondary Packing: The store will be supplied in the packing as approved by the NPPA.

Technical Specifications of Primary & Secondary Packing:-

- i. Aluminium/Blister - 25 Micron
- ii. Aluminium/Strip - 30 Micron
- iii. 5 Ply Corrugated Box G.S.M.:- 1) 1st layer,- 240,  
2) 2nd, 4th,- 100 each,  
3) 3rd, 5th,- 80 each,  
B.S.:- NLT 9Kg/cm<sup>2</sup>
- iv. PVC (Rigid PVC film uncoated) - 250 micron

1. PVDC (Rigid PVC film coated with polyvinylidene chloride (PVDC) - 250 micron/60 GSM

Efluite -

G.S.M of layers:-

1. a) White duplex (outer) - 310

2. b) Narrow fluite (semi craft brown):- 100
3. c) Semi craft paper brown: 100

B.S.:- NLT 5 Kg/cm<sup>2</sup>

#### 1. Marking:

Each packing shall also be marked with:

1. a) Manufacturer's name and address.
2. b) Batch No. License No. and date of manufacture and date of expiry.
3. c) Quantity contained therein.
4. d) Any other particulars as specified under Drugs and Cosmetics Act. 1940 as amended to date.

#### 1.2 Special Terms and Condition for 103 Drugs reserved for Central Public Sector Enterprises (CPSEs)

1. Pharmaceuticals Purchase Policy by Department of Pharmaceuticals, Ministry of Chemical and Fertilizers, GOI in respect of 103 (one hundred and three) medicines would be valid for a period of five years from the date of issue of orders (10th Dec 2013).
2. Pharmaceuticals Purchase Policy will extend only to Central Public Sector Enterprises (CPSEs) under the administrative control of Department of Pharmaceuticals such as Indian Drugs and Pharmaceuticals Limited (IDPL), Hindustan Antibiotics Limited (HAL), Bangal Chemicals and Pharmaceuticals Limited (BCPL), Karnataka Antibiotics and Pharmaceuticals Limited (KAPL) and Rajasthan Drugs and Pharmaceuticals Limited (RDPL) and their subsidiaries where Government of India owns 51% (fifty one percent) or above shares.
3. This would be applicable to purchases by Central Government Departments, there Public Sector Undertakings, and Autonomous Bodies, etc. This would also be applicable to purchase of medicines by State Governments under Health Programmes funded by Government of India such as the National Rural Health Mission etc.
4. The pricing of these drugs would be done by National Pharmaceutical Pricing Authority (NPPA) using the cost based formula as mentioned in the Drugs Price Control Order, 1995. The latest prices are fixed by NPPA including 16% discount vide F.No. 51017/01/2013-PSU (Vol. II) dated 08.08.2017. In case the prices are revised downward by the NPPA, prices will be changed accordingly and reduced rate shall be applicable for all supplies made on or after the date of reduction.
5. All Provision of Drug & Cosmetic act 1940 as amended till date and rules made there under will always be applicable.
6. In case pharma CPSEs and their subsidiaries fail supply the medicines, the buyer would be at liberty to make purchases from other manufacturers. If the pharms CPSEs or their subsidiaries fail to perform as per the contract, they would also be subject to payment of liquidated damages or any other penalty as per the terms of the contract.
7. Drug License - CPSEs should hold valid drug license/import License from the concerned drug controller for the manufacturer/import of the medicine/drug. If revalidation of drug license has been applied for, the buyer should be informed accordingly and the copy of application to State Drug/Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has been deleted by licensing authority.
8. CPSEs should have valid Good Manufacturing Practice (GMP/WHO-GMP) as per revised schedule M of the Drugs & Cosmetic Rules for indigenous drugs. GMP certificate if revalidated/extended during the bid period, the same to be informed to the buyer.
9. CPSEs should have valid Non-Conviction Certificate from the concerned drug controller.
10. Loan license arrangement shall not be allowed under any circumstances.
11. Each batch of the drugs shall be dispatched under self-certification scheme duly supported by their own test reports. The consignees shall be at liberty to draw control samples and send it to laboratories approved by the State Drug Controllers / run by State Government/NABL approved laboratories without any intimation to the supplier. If the new test report is contradictory with the test report submitted, the cost incurred on the whole process of testing shall be borne by the seller. Also, if at any stage of use the supplies are found substandard, NO PAYMENT will be made for the entire rejected/substandard batch of that particular item, even if the supplies have been consumed in good faith and the facts will be notified to the Drug Controller if India / State Drug Controller for taking necessary action.
12. The classification of defects into different categories will be as per guidelines issued by the Drug Controller of India and action will be taken accordingly.
13. Losses if any due to biological deterioration of the product during the shelf life of potency will be made good by the seller.
14. The supplies should not have passed more than 1/6th of the total shelf life of the product at the time of receipt of the store.
15. It is the responsibility of the seller to intimate Government e-Marketplace (GEM) about any quality complaints of the drugs/medicines reported by any buyer/consignee.
16. Order should be placed for the quantities in multiples of the primary packing.
17. Minimum lead time for delivery will be 60 days.
18. Bar coding - The buyer can opt for bar coding only if the order placed on any CPSE is for minimum quantity of tablet/capsule- 5.0 lakhs numbers or injection- 1.0 lakh number or ointment- 25000 numbers or syrup- 5000 numbers. The bar coding will be GSI complied.
19. Labels of all containers, cartons, vials, strips etc. should invariably be marked in block letters "Government supply not for sale" with the indelible ink for supplies made to the Government.
20. PACKING & MARKING: Packing and Marking will be as per provisions of applicable Pharmacopeia and as specified under Drugs and Cosmetics Act. 1940 as amended to date. In addition-

A) Primary and Secondary Packing: The store will be supplied in the packing as approved by the NPPA.

Technical Specifications of Primary & Secondary Packing:-

- i. Aluminium/Blister - 25 Micron
- ii. Aluminium/Strip - 30 Micron
- iii. 5 Ply Corrugated Box G.S.M.:- 1) 1st layer,- 240,

2) 2nd, 4th,- 100 each,

3) 3rd, 5th,- 80 each,

B.S.:- NLT 9Kg/cm<sup>2</sup>

iv. PVC (Rigid PVC film uncoated) - 250 micron V. PVDC (Rigid PVC film coated with polyvinylidene chloride (PVDC) - 250 micron/60 GSM) Efluite - G.S.M of layers:- a) White duplex (outer) - 310 b) Narrow fluite (semi craft brown):- 100 c) Semi craft paper brown: 100 B.S.:- NLT 5 Kg/cm<sup>2</sup>

B) Marking: Each packing shall also be marked with: a) Manufacturer's name and address. b) Batch No. License No. and date of manufacture and date of expiry. c) Quantity contained therein. d) Any other particulars as specified under Drugs and Cosmetics Act. 1940 as amended to date.

### 1.3 Special Terms and Condition for 103 Drugs reserved for Central Public Sector Enterprises (CPSEs)

1.3.1 Pharmaceuticals Purchase Policy by Department of Pharmaceuticals, Ministry of Chemical and Fertilizers, GOI in respect of 103 (one hundred and three) medicines would be valid for a period of five years from the date of issue of orders (10th Dec 2013).

1.3.2 Pharmaceuticals Purchase Policy will extend only to Central Public Sector Enterprises (CPSEs) under the administrative control of Department of Pharmaceuticals such as Indian Drugs and Pharmaceuticals Limited (IDPL), Hindustan Antibiotics Limited (HAL), Bengal Chemicals and Pharmaceuticals Limited (BCPL), Karnataka Antibiotics and Pharmaceuticals Limited (KAPL) and Rajasthan Drugs and Pharmaceuticals Limited (RDPL) and their subsidiaries where Government of India owns 51% (fifty one percent) or above shares.

1.3.3 This would be applicable to purchases by Central Government Departments, their Public Sector Undertakings, and Autonomous Bodies, etc. This would also be applicable to purchase of medicines by State Governments under Health Programmes funded by Government of India such as the National Rural Health Mission etc.

1.3.4 The pricing of these drugs would be done by National Pharmaceutical Pricing Authority (NPPA) using the cost based formula, as mentioned in the Drugs Price Control Order, 1995. The latest prices are fixed by NPPA including 16% discount vide F. No. 51017/01/2013-PSU(Vol. II) dated 08.08.2017. In case the prices are revised downward by the NPPA, prices will be changed accordingly and reduced rate shall be applicable for all supplies made on or after the date of reduction.

1.3.5 All Provision of Drug & Cosmetic act 1940 as amended till date and rules made there under will always be applicable.

1.3.6 In case pharma CPSEs and their subsidiaries fail to supply the medicines, the buyer would be at liberty to make purchases from other manufacturers. If the pharma CPSEs or their subsidiaries fail to perform as per the contract, they would also be subject to payment of liquidated damages or any other penalty as per the terms of the contract.

1.3.7 Drug License -CPSEs should hold valid drug license / import License from the concerned drug controller for the manufacture / import of the medicine/drug. If revalidation of drug license has been applied for, the buyer should be informed accordingly and the copy of application to State Drug / Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has not been deleted by licensing authority.

1.3.8 CPSEs should have valid Good Manufacturing Practice (GMP / WHO-GMP) as per revised schedule M of the Drugs & Cosmetic Rules for indigenous drugs. GMP certificate if revalidated/ extended during the bid period, the same to be informed to the buyer.

1.3.9 CPSEs should have valid Non-Conviction Certificate from the concerned drug controller.

1.3.10 Loan license arrangement shall not be allowed under any circumstances.

1.3.11 Each batch of the drugs shall be dispatched under self-certification scheme duly supported by their own test reports. The consignees shall be at liberty to draw control samples and send it to laboratories approved by State Drug controllers / run by State Government/NABL approved laboratories without any intimation to the supplier. If the new test report is contradictory with the test report submitted, the cost incurred on the whole process of testing shall be borne by the seller. Also, if at any stage of use the supplies are found substandard, NO PAYMENT will be made for the entire rejected / substandard batch of that particular item, even if the supplies have been consumed in good faith and the facts will be notified to the Drug Controller of India / State Drug Controller for taking necessary action.

1.3.12 The classification of defects into different categories will as per guidelines issued by the Drug Controller of India and action will be taken accordingly.

1.3.13 The supplies should not have passed more than 1/6th of the total shelf life of the product at the time of receipt of the store.

1.3.14 It is the responsibility of the seller to intimate Government e-Marketplace (GEM) about any quality complaints of the drugs/medicines reported by any buyer/consignee.

1.3.15 Order should be placed for the quantities in multiples of the primary packing.

1.3.16 Minimum lead time for delivery will be 60 days.

1.3.17 Bar coding- The buyer can opt for bar coding only if the order placed on any CPSE is for minimum quantity of tablet/capsule- 5.0 lakhs numbers or injection- 1.0 lakh number or ointment-25000 numbers or syrup -5000 numbers. The bar coding will be GS1 complied.

1.3.18 Labels of all containers, cartons, wrappers, vials, strips etc. should invariably be marked in block letters "Government supply not for sale" with the indelible ink for supplies made to the Government.

1.3.19 PACKING & MARKING: Packing and Marking will be as per provisions of applicable Pharmacopeia and as specified under Drugs and Cosmetics Act. 1940 as amended to date. In addition-

1.3.19.1 Primary and Secondary Packing: The stores will be supplied in the packing as approved by the NPPA.

1.3.19.1.1 Technical Specifications of Primary & Secondary Packing:-

i. Aluminium / Blister - 25 Micron

ii. Aluminium / Strip - 30 Micron

iii. 5 Ply Corrugated Box G.S.M.: -

1) 1st layer: - 240 ,

2) 2nd, 4th, - 100 each,

3) 3rd, 5th, - 80 each,

B.S.: - NLT 9Kg / cm2

iv. PVC (Rigid PVC film uncoated) - 250 micron

v. PVDC (Rigid PVC film coated with polyvinylidene chloride (PVDC) - 250 micron / 60 GSM

1.3.19.1.2 Effluite -

G.S.M of layers: -

a) White duplex (outer) 310

b) Narrow fluite (semi craft brown): - 100

c) Semi craft paper brown: 100

B.S.: - NLT 5 Kg / cm2.

1.3.19.2 Marking :

1.3.19.2.1 Each packing shall also be marked with:

a) Manufacturer's name and address.

b) Batch No. License No. and date of manufacture and date of expiry.

c) Quantity contained therein.

d) Any other particulars as specified under Drugs and Cosmetics Act. 1940 as amended to date.

## 2. General Terms and Conditions-

2.1 This contract is governed by the [General Terms and Conditions](#), conditions stipulated to this Product/Service as provided in the Marketplace.

2.2 This Contract between the Seller and the Buyer, is for the supply of the Goods and/ or Services, detailed in the schedule above, in accordance with the General Terms and Conditions (GTC) unless otherwise superseded by Goods / Services specific Special Terms and Conditions (STC) and/ or BID/Reverse Auction Additional Terms and Conditions (ATC), as applicable

Note: This is system generated file. No signature is required. Print out of this document is not valid for payment/ transaction purpose.